These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Disappointing results for vicriviroc. AIDS Patient Care STDS; 2010 Mar; 24(3):197-8. PubMed ID: 20238442 [No Abstract] [Full Text] [Related]
3. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. Klibanov OM Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929 [TBL] [Abstract][Full Text] [Related]
4. Long-term data on vicriviroc released. AIDS Patient Care STDS; 2009 Nov; 23(11):989. PubMed ID: 19938348 [No Abstract] [Full Text] [Related]
5. Anti-HIV agents. Vicriviroc: is the risk of cancer increased? TreatmentUpdate; 2006; 18(4):5-6. PubMed ID: 17209230 [No Abstract] [Full Text] [Related]
6. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR; J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119 [TBL] [Abstract][Full Text] [Related]
7. Better results from vicriviroc with new Trofile test. Proj Inf Perspect; 2008 Dec; (47):12. PubMed ID: 19227563 [No Abstract] [Full Text] [Related]
8. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Kümmerle T; Lehmann C; Hartmann P; Wyen C; Fätkenheuer G Expert Opin Investig Drugs; 2009 Nov; 18(11):1773-85. PubMed ID: 19888873 [TBL] [Abstract][Full Text] [Related]
9. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705 [TBL] [Abstract][Full Text] [Related]
11. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges. Lenz JC; Rockstroh JK Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1139-50. PubMed ID: 20712521 [TBL] [Abstract][Full Text] [Related]
12. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072 [TBL] [Abstract][Full Text] [Related]
13. More problems with entry inhibitor. AIDS Patient Care STDS; 2006 May; 20(5):380. PubMed ID: 16758552 [No Abstract] [Full Text] [Related]
14. New CCR5 antagonist enters phase II trials. Drug would be first-line therapy. AIDS Alert; 2008 Aug; 23(8):89-90. PubMed ID: 18724488 [No Abstract] [Full Text] [Related]
16. Rhinocerebral zygomycosis in an HIV-infected man during therapy with an investigational CCR5 inhibitor. Merchant S; Reichman R; Koval CE AIDS; 2007 Jul; 21(12):1666-9. PubMed ID: 17630574 [No Abstract] [Full Text] [Related]
17. CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged. McNiff T; Dezube BJ AIDS Read; 2009; 19(6):218-22, 224. PubMed ID: 19642239 [No Abstract] [Full Text] [Related]
18. CCR5 inhibitors: up and coming new agents. O'Neal R BETA; 2007; 19(2):15-9. PubMed ID: 17489112 [TBL] [Abstract][Full Text] [Related]
19. Targeting the chemokine receptor CCR5: good for HIV, what about other viruses? Keynan Y; Juno J; Kasper K; Rubinstein E; Fowke KR J Infect Dis; 2011 Jan; 203(2):292; author reply 293. PubMed ID: 21288830 [No Abstract] [Full Text] [Related]